Home
World Journal of Advanced Research and Reviews
International Journal with High Impact Factor for fast publication of Research and Review articles

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

eISSN: 2582-8185 || CODEN: WJARAI || Impact Factor 8.2 ||  CrossRef DOI

Research and review articles are invited for publication in March 2026 (Volume 29, Issue 3) Submit manuscript

Complete remission with Immunotherapy in second-Line in metastatic lung cancer without targetable oncogenic addiction: About a case and revue of the literature

Breadcrumb

  • Home
  • Complete remission with Immunotherapy in second-Line in metastatic lung cancer without targetable oncogenic addiction: About a case and revue of the literature

M Belhouari 1, S Khalfi 1, 2, *, C Khalfi 3, N Benchakroune 1, M Bourhafour 1, T Chekrine 1, Z Bouchbika 1, N Tawfik 1, H Jouhadi 1, Z Alami 2, T Bouhafa 2, A Benider 1 and S Sahraoui 1

1 Mohamed VI center for the treatment of cancer, Casablanca.
2 Department of Radiotherapy, Hassan II university hospital, Fez.
3 internal medecine department, Ibn Rochd university hospital, Casablanca.
 
Case Study
World Journal of Advanced Research and Reviews, 2023, 17(03), 598–601
Article DOI: 10.30574/wjarr.2023.17.3.0370
DOI url: https://doi.org/10.30574/wjarr.2023.17.3.0370
 
Received on 25 January 2023; revised on 11 March 2023; accepted on 14 March 2023
 
Lung cancer is a public health problem in the world, en 2020: 2nd most common cancer after breast cancer. Smoking is the main risk factor constituting an essential axis of prevention. Non-small cell lung cancer is the most common histological component representing approximately 85%, currently 75% of patients have unfortunately become at advanced stages, the prognosis remains poor: incidence and expectation are close, but metastatic NSCLC has experienced a total renewal of the therapeutic arsenal. It is a model of precision medicine and also in particular a model for immunotherapy. We are recently faced with an expanded therapeutic arsenal posing a problem of choice. with a durable complete response with Atezolizumab.
 
Metastatic Lung cancer; Chemotherapy PDL-1; Atezolizumab; Case
 
https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2023-0370.pdf

Preview Article PDF

M Belhouari, S Khalfi, C Khalfi, N Benchakroune, M Bourhafour, T Chekrine, Z Bouchbika, N Tawfik, H Jouhadi, Z Alami, T Bouhafa, A Benider and S Sahraoui. Complete remission with Immunotherapy in second-Line in metastatic lung cancer without targetable oncogenic addiction: About a case and revue of the literature. World Journal of Advanced Research and Reviews, 2023, 17(3), 598-601. Article DOI: https://doi.org/10.30574/wjarr.2023.17.3.0370

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.

All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 International Journal of Science and Research Archive - All rights reserved

Developed & Designed by VS Infosolution